|
Dr. Goundis holds a Ph.D. in Biochemistry from the University of Oxford, a B.Sc. in Chemistry/Biochemistry from the University of London and a Certificate in Investment Management from the London Business School. From 1988 until 2006, he spent several years in the Pharmaceutical Industry, both in big Pharma (e.g. Hoffman La Roche) and in start-up companies, first The Medicines Company Inc., and then Speedel AG. He started at Hoffman La Roche in Research, then proceeded in Clinical Research, and later he was appointed as International Project Director leading multidisciplinary teams in drug development.
At The Medicines Company Inc., he was Senior Director for Project Management and following its successful IPO on Nasdaq in August 2000, he joined Speedel AG, a BioPharmaceutical company based in Basel, Switzerland. There he held several different positions of high responsibility, starting as Project Director, then Head of Project Management and finally Managing Director of Speedel Experimenta. Speedel AG was successfully listed on the Swiss Stock Exchange in September 2005. | 